1. Oral doses of 10-100 mg/kg of
BRL 13776 lowered the blood pressure of both
deoxycorticosterone acetate (
DOCA)/NaCl-treated hypertensive rats and untreated normotensive rats. 2.
BRL 13776 (100 mg/kg, orally) also reduced the blood pressure of renal hypertensive cats (
cellophane perinephritis model). 3. No tolerance developed to the blood-pressure lowering action of
BRL 13776 when an oral daily dose of 100 mg/kg was administered repeatedly for up to 15 days to hypertensive rats and cats. 4. The fall in blood pressure to
BRL 13776 in rats was associated with a reduction of tissue
catecholamines. 5. The
catecholamine depletion occurred in all the peripheral tissues examined but in the brain was restricted to certain regions, these being the hind-brain on single dosing and the hind-brain, hypothalamus and mid-brain on repeated dosing.
Catecholamine levels in the cerebral hemispheres were not affected by either single or repeated doses of
BRL 13776. 6.
BRL 13776 caused some reduction of the
5-hydroxytryptamine content of the heart but not of whole brain or any brain region. 7. Neither single doses (up to 900 mg/kg orally) nor repeated doses (100-300 mg/kg orally) of
BRL 13776 produced any significant behavioural effects in animals. 8.
BRL 13776 is a new type of agent to display both
antihypertensive and monoamine-depleting properties. The reduction of
noradrenaline in certain brain regions may be a cause of the
antihypertensive response but depletion in the periphery could contribute in a major or minor way. The differential action on
noradrenaline in the brain together with the lack of effect on
5-hydroxytryptamine might also explain the apparent absence of behavioural effects.